8-K Announcements
6Material company update
Nov 13, 2025·SEC
Material company update
Nov 12, 2025·SEC
Material company update
Aug 11, 2025·SEC
BioVie Inc.(BIVI)Earnings, Financials & Key Ratios
BIVI•NASDAQ
$1.94
Price updated Jun 27, 2026
AboutBioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.Show more
- Revenue$0
- EBITDA-$18M+44.2%
- Net Income-$18M+45.4%
- EPS (Diluted)-12.12+83.4%
- ROE-101.64%+51.2%
BIVI Price & Volume
BioVie Inc. (BIVI) stock price & volume — 10-year historical chart
Loading chart...
Clinical Stagnation Drives Persistent Capital Erosion Risk
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial data integrity
"BioVie remains a high-risk, pre-revenue biotechnology entity currently facing significant headwinds due to clinical trial protocol deviations that have stalled its primary development pipeline. The company's reliance on equity-based financing to sustain operations, evidenced by an accumulated deficit of $368.6 million, creates a precarious outlook for long-term shareholder value. Investors should monitor the company's ability to secure additional capital, as the current cash position of $13.1 million may prove insufficient to support ongoing research requirements."
Verdict Logic
the company's cash position has declined to $13.1 million from a peak of $30.4 million in 2024Q3, suggesting an imminent liquidity crisis that may necessitate highly dilutive financing.
BIVI Growth Metrics
BioVie Inc. (BIVI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.05%
Return on Capital
10 Years-443.46%
5 Years-703.82%
3 Years-175.32%
Last Year-102.81%
BIVI Recent Earnings
BioVie Inc. (BIVI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.70+4.1%
$0.73
Rev
—
—
Q1 2026
Feb 6, 2026Metric
Actual
Est
EPS
$0.77+4.9%
$0.81
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.98-24.1%
$0.79
Rev
—
—
Q3 2025
Aug 15, 2025Metric
Actual
Est
EPS
$0.24+94.6%
$4.40
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.70vs $0.73+4.1% | — |
| Q1 2026 | Feb 6, 2026 | $0.77vs $0.81+4.9% | — |
| Q4 2025 | Nov 10, 2025 | $0.98vs $0.79-24.1% | — |
| Q3 2025 | Aug 15, 2025 | $0.24vs $4.40+94.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioVie Inc. (BIVI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.94 | $14.64M | -0.16 | — | — | -101.64% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $87.32 | $9.37B | 106.49 | 12.79% | 6.23% | 7.5% | — |
Compare BIVI vs Peers
BioVie Inc. (BIVI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIVI SEC Filings & Documents
BioVie Inc. (BIVI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BIVI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BIVI Frequently Asked Questions
BioVie Inc. (BIVI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BIVI profitable?
BioVie Inc. (BIVI) reported a net loss of $19.9M for fiscal year 2025.
Dividend & Returns
What is BIVI's return on equity?
BioVie Inc. (BIVI) has a return on equity (ROE) of -101.6%. Negative ROE indicates the company is unprofitable.
What is BioVie Inc.'s free cash flow?
BioVie Inc. (BIVI) had negative free cash flow of $20.5M in fiscal year 2025, likely due to heavy capital investments.